Flerie AB (FRA:1NP1) Short Interest


FRA:1NP1 Flerie AB FRA:1NP1
27 GF Score
Price €1.71
! 1 Warning Sign
View Full Analysis

What is Flerie AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:1NP1 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Flerie AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Flerie AB Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Flerie AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Flerie AB's Short Interest falls into.


FRA:1NP1
27GF Score
Flerie AB FRA:1NP1
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Flerie AB Business Description

Other Exchanges FLERIE:Sweden1NP1:Germany
Address Skeppsbron 16, Stockholm, SWE, 111 30
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
27GF Score

Get the complete analysis for FRA:1NP1

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.71
Price